CEP-14513
CEP-14513 is an ALK inhibitor with an IC50 of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, TIE2 and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 856693-04-4
- Formule: C34H36N6O3
- Masse moléculaire:576.70
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform VEGFR
MoreVoir tous les produits spécifiques à Isoform MAP3K
More
Activité biologique
|
VEGFR2 |
Tie2 |
MAP3K12/DLK |
CEP-14513 inhibits the proliferation of ALK-mutant cell lines, with a cellular IC50 value of 10-30 nM[1].
CEP-14513 potently inhibits purified NPM-ALK fusion kinase with an IC50 < 5 nM, while it shows no inhibitory activity against CDK1/CDK2/CDK5, MET and IKKβ[2].
CEP-14513 inhibits tyrosine phosphorylation in NPM-ALK-transformed cells, with an IC50 < 30 nM[2].
CEP-14513 selectively inhibits proliferation and colony formation of NPM-ALK-transformed cells, and induces their apoptosis, while exhibits extremely low activity against ALK-negative K562 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 856693-04-4
-
Masse moléculaire 576.70
-
Formule C34H36N6O3
-
SMILES
O=C(OC1=CC=C2C(=C1)C=3C(=C4C(C5=CN(N=C5CC4)C)=C6C(=O)NCC63)N2CC(C)C)NCC7=CC=C(C=C7)N(C)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1].
Puig de la Bellacasa R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013 Apr;2(2):72-86.
[Content Brief]
[2]. Gunby RH, et al. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. Anticancer Agents Med Chem. 2007;7(6):594-611. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz